By proceeding, you agree to our Terms of Use and Privacy Policy.
Whilst still in infancy, the rise of multispecific drugs that drive induced proximity between otherwise disparate biological targets is shifting the drug discovery paradigm towards therapeutic interventions for previously undrugged, or hard-to-drug targets with clinical value. As the only industry dedicated forum to radically advance heterobifunctional drug discovery, the 3rd Induced Proximity-Based Drug Discovery Summit is set to unite 50+ key leaders in biopharma and academia who are eager to take a deeper dive into early drug discovery, protein interactions and the novel modalities that are emerging in the space. Hear from 22+ expert speakers across 3 days of data-driven presentations, technical workshops, and panel discussions to push the therapeutic limits of the field. This is an exclusive opportunity to discover better binders, design efficient heterobifunctionals and accelerate proof of concept gain at the only summit focused on helping you progress your induced proximity pipelines from conception to clinic.
Gain insights into medicinal chemistry, drug discovery, and biochemistry.
Take a deep dive into targeted protein stabilization. Also, learn about advancedscreening, strategies for hit, discovery and predicting protein.
Promote cooperative protein interactions, and solve protein structures with a stimulating workshop and focused sessions from the University of Michigan, Western Case Reserve University and Icahn School of Medicine, Mt. Sinai.
Meet like-minded experts and enthusiasts working at the cutting edge of medicinal chemistry, drug discovery, and biochemistry to get inspired.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems.
Visualizing biomolecular structures through cryo-EM studies can provide insight into multiple stages of the drug development process, from target identification through formulation and manufacturing.
NEOsphere Biotechnologies is a pioneering proteomics company that creates value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets not yet exploited.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.